A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Orforglipron, Placebo.
- Who it may be relevant to
- Registry conditions: Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease. Basic parameters: from 50 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Argentina, Australia, Austria, Belgium, Brazil +33
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
Overview
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Interventions
- Drug Orforglipron
Administered orally - Drug Placebo
Administered orally
Primary outcome measures
- Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events [Time frame: Baseline up to end of study (about 5 years)]
Secondary outcome measures (3)
- Time to First Occurrence of Composite Endpoint of Major Cardiovascular and Kidney Events [Time frame: Baseline up to end of study (about 5 years)]
- Change from Baseline in Total eGFR Slope [Time frame: Baseline up to end of study (about 5 years)]
- Time to Onset of Type 2 Diabetes [Time frame: Baseline up to end of study (about 5 years)]
Eligibility criteria
Inclusion criteria
- Have established ASCVD and/or CKD
Exclusion criteria
- Have type 1 diabetes
- Have had a major heart condition within 60 days prior to screening
- Have New York Heart Association Functional Classification Class IV heart failure
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Argentina · 59 centers
- Instituto de Investigaciones Clínicas Bahia Blanca — Bahía Blanca
- CONEXA Investigacion Clinica S.A. — Buenos Aires
- Buenos Aires Macula S.A — Buenos Aires
- CIPREC — Buenos Aires
- Instituto Médico Especializado (IME) — Buenos Aires
- Cicemo Srl — Buenos Aires
- Cardiología Palermo — Buenos Aires
- Consultorio Medico Investigador Principal Dr Besada — Buenos Aires
- … and 51 more centers
Mexico · 35 centers
Center list to be confirmed — check the primary protocol.
Brazil · 34 centers
Center list to be confirmed — check the primary protocol.
China · 29 centers
Center list to be confirmed — check the primary protocol.
Netherlands · 23 centers
Center list to be confirmed — check the primary protocol.
India · 20 centers
Center list to be confirmed — check the primary protocol.
Poland · 20 centers
Center list to be confirmed — check the primary protocol.
Romania · 20 centers
Center list to be confirmed — check the primary protocol.
Canada · 19 centers
Center list to be confirmed — check the primary protocol.
Ukraine · 19 centers
Center list to be confirmed — check the primary protocol.
South Korea · 18 centers
Center list to be confirmed — check the primary protocol.
Israel · 17 centers
Center list to be confirmed — check the primary protocol.
Belgium · 16 centers
Center list to be confirmed — check the primary protocol.
Spain · 16 centers
Center list to be confirmed — check the primary protocol.
Australia · 15 centers
- Nightingale Research — Adelaide
- Paratus Clinical Research Western Sydney — Blacktown
- Box Hill Hospital — Box Hill
- Royal Brisbane and Women's Hospital — Brisbane
- Paratus Clinical Research Canberra — Bruce
- Emeritus Research — Camberwell
- Nightingale Research - Frankston — Frankston
- Canberra Hospital — Garran
- … and 7 more centers
Hungary · 15 centers
Center list to be confirmed — check the primary protocol.
Italy · 15 centers
Center list to be confirmed — check the primary protocol.
Taiwan · 15 centers
Center list to be confirmed — check the primary protocol.
Turkey (Türkiye) · 15 centers
Center list to be confirmed — check the primary protocol.
Czechia · 14 centers
Center list to be confirmed — check the primary protocol.
France · 13 centers
Center list to be confirmed — check the primary protocol.
Colombia · 11 centers
Center list to be confirmed — check the primary protocol.
Slovakia · 11 centers
Center list to be confirmed — check the primary protocol.
Bulgaria · 10 centers
Center list to be confirmed — check the primary protocol.
Japan · 10 centers
Center list to be confirmed — check the primary protocol.
Philippines · 10 centers
Center list to be confirmed — check the primary protocol.
Austria · 8 centers
- VIVIT — Feldkirch
- Medizinische Universität Graz — Graz
- Ordensklinikum Linz GmbH Elisabethinen — Linz
- Cardio Metabolic Centre — Mattersburg
- Private Practice - Dr. Evelyn Fliesser-Gorzer — Sankt Stefan ob Stainz
- Klinik Hietzing — Vienna
- … and 2 more centers
Germany · 8 centers
Center list to be confirmed — check the primary protocol.
Greece · 8 centers
Center list to be confirmed — check the primary protocol.
United Kingdom · 8 centers
Center list to be confirmed — check the primary protocol.
Lithuania · 7 centers
Center list to be confirmed — check the primary protocol.
New Zealand · 6 centers
Center list to be confirmed — check the primary protocol.
Serbia · 5 centers
Center list to be confirmed — check the primary protocol.
South Africa · 5 centers
Center list to be confirmed — check the primary protocol.
Estonia · 4 centers
Center list to be confirmed — check the primary protocol.
Malaysia · 4 centers
Center list to be confirmed — check the primary protocol.
Thailand · 3 centers
Center list to be confirmed — check the primary protocol.
Tunisia · 2 centers
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07241390 · 27771 · J2A-MC-GZPW · 2025-523123-22-00